FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620873665> ?p ?o ?g. }

• W2620873665 endingPage "1815" @default.
• W2620873665 startingPage "1815" @default.
• W2620873665 abstract "Abstract BACKGROUND Nodal peripheral T-cell lymphomas (PTCLs), except ALK-positive anaplastic large cell lymphoma (ALCL) have inferior outcomes compared with their B-cell counterparts. CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) is considered the standard therapy despite consistent results showing its ineffectiveness. The addition of etoposide (E) to chemotherapy showed encouraging results in selected subgroups of patients. We performed a matched-pair analysis comparing the efficacy of EPOCH to CHOP for untreated patients with nodal PTCLs, excluding ALK-positive ALCL. PATIENTS AND METHODS According to the Thai Lymphoma Study Group uniform treatment project, 58 patients with nodal PTCLs including angioimmunoblastic lymphoma, ALK-negative ALCL and PTCL, not otherwise specified received conventional EPOCH regimen as frontline therapy between January 2009 and December 2015. These patients were matched to 58 patients receiving CHOP (1:1) in multicenter registry of lymphoma in Thailand between 2007-2014 by center, International Prognostic Index (IPI) and age. Patients who underwent upfront autologous stem cell transplantation (ASCT) were censored at the time of transplantation. RESULTS The baseline characteristics were well balanced between the two groups except a higher proportion of patients with ALK-negative ALCL in EPOCH group (24.1% vs 5.2%) (Table 1). The median cycle of chemotherapy was 6 (range, 1-8) in both groups. Four patients (6.9%) underwent upfront ASCT after EPOCH induction. The overall response rate for evaluable patients were 75.4% (complete response [CR] 57%) and 58% (CR 39%) in EPOCH and CHOP groups, respectively (P<0.0001). With a median follow up of 26 months, 4-year progression free survival (PFS) were 45.8% and 26.7% in EPOCH and CHOP group, respectively (P=0.022) (Figure 1). Projected overall survival (OS) at 4 years were 50.9% and 28.7% for EPOCH- and CHOP-treated patients, respectively (P=0.001) (Figure 2). By multivariate analysis, chemotherapy regimen was the only factor independently predicting PFS (Hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.04-3.19, P=0.034) and OS (HR 2.26, 95% CI 1.28-3.97, P=0.005). CONCLUSION EPOCH provided superior outcomes than CHOP regimen as frontline therapy for patients with nodal PTCLS, excluding ALK-positive ALCL. The promising efficacy of EPOCH warrants further evaluation in prospective randomized controlled study. Table 1 Baseline characteristics of patients with nodal PTCLs treated with EPOCH or CHOP regimens Table 1. Baseline characteristics of patients with nodal PTCLs treated with EPOCH or CHOP regimens Figure 1 Kaplan Meier progression free survival of patients with untreated nodal PTCLs according to chemotherapy regimens Figure 1. Kaplan Meier progression free survival of patients with untreated nodal PTCLs according to chemotherapy regimens Figure 2 Kaplan Meier overall survival of patients with untreated nodal PTCLs according to chemotherapy regimens Figure 2. Kaplan Meier overall survival of patients with untreated nodal PTCLs according to chemotherapy regimens Disclosures No relevant conflicts of interest to declare." @default.
• W2620873665 created "2017-06-09" @default.
• W2620873665 creator A5001634662 @default.
• W2620873665 creator A5013605465 @default.
• W2620873665 creator A5017142727 @default.
• W2620873665 creator A5017193608 @default.
• W2620873665 creator A5043187515 @default.
• W2620873665 creator A5046486904 @default.
• W2620873665 creator A5050237877 @default.
• W2620873665 creator A5052903150 @default.
• W2620873665 creator A5058153938 @default.
• W2620873665 creator A5058943669 @default.
• W2620873665 creator A5065104304 @default.
• W2620873665 creator A5074815016 @default.
• W2620873665 creator A5076137762 @default.
• W2620873665 creator A5089927021 @default.
• W2620873665 date "2016-12-02" @default.
• W2620873665 modified "2023-10-14" @default.
• W2620873665 title "A Matched-Pair Analysis of EPOCH Versus CHOP As Frontline Therapy for Nodal Peripheral T-Cell Lymphoma, Excluding ALK-Positive Anaplastic T-Cell Lymphoma: A Multicenter Experience in Thailand" @default.
• W2620873665 doi "https://doi.org/10.1182/blood.v128.22.1815.1815" @default.
• W2620873665 hasPublicationYear "2016" @default.
• W2620873665 type Work @default.
• W2620873665 sameAs 2620873665 @default.
• W2620873665 citedByCount "2" @default.
• W2620873665 countsByYear W26208736652022 @default.
• W2620873665 countsByYear W26208736652023 @default.
• W2620873665 crossrefType "journal-article" @default.
• W2620873665 hasAuthorship W2620873665A5001634662 @default.
• W2620873665 hasAuthorship W2620873665A5013605465 @default.
• W2620873665 hasAuthorship W2620873665A5017142727 @default.
• W2620873665 hasAuthorship W2620873665A5017193608 @default.
• W2620873665 hasAuthorship W2620873665A5043187515 @default.
• W2620873665 hasAuthorship W2620873665A5046486904 @default.
• W2620873665 hasAuthorship W2620873665A5050237877 @default.
• W2620873665 hasAuthorship W2620873665A5052903150 @default.
• W2620873665 hasAuthorship W2620873665A5058153938 @default.
• W2620873665 hasAuthorship W2620873665A5058943669 @default.
• W2620873665 hasAuthorship W2620873665A5065104304 @default.
• W2620873665 hasAuthorship W2620873665A5074815016 @default.
• W2620873665 hasAuthorship W2620873665A5076137762 @default.
• W2620873665 hasAuthorship W2620873665A5089927021 @default.
• W2620873665 hasConcept C121332964 @default.
• W2620873665 hasConcept C126322002 @default.
• W2620873665 hasConcept C1276947 @default.
• W2620873665 hasConcept C141071460 @default.
• W2620873665 hasConcept C143998085 @default.
• W2620873665 hasConcept C150846664 @default.
• W2620873665 hasConcept C2776694085 @default.
• W2620873665 hasConcept C2776755627 @default.
• W2620873665 hasConcept C2777872185 @default.
• W2620873665 hasConcept C2778119113 @default.
• W2620873665 hasConcept C2778336483 @default.
• W2620873665 hasConcept C2778476033 @default.
• W2620873665 hasConcept C2778559949 @default.
• W2620873665 hasConcept C2779050716 @default.
• W2620873665 hasConcept C2779338263 @default.
• W2620873665 hasConcept C2779429289 @default.
• W2620873665 hasConcept C2779725641 @default.
• W2620873665 hasConcept C2780317896 @default.
• W2620873665 hasConcept C2911091166 @default.
• W2620873665 hasConcept C71924100 @default.
• W2620873665 hasConcept C90924648 @default.
• W2620873665 hasConceptScore W2620873665C121332964 @default.
• W2620873665 hasConceptScore W2620873665C126322002 @default.
• W2620873665 hasConceptScore W2620873665C1276947 @default.
• W2620873665 hasConceptScore W2620873665C141071460 @default.
• W2620873665 hasConceptScore W2620873665C143998085 @default.
• W2620873665 hasConceptScore W2620873665C150846664 @default.
• W2620873665 hasConceptScore W2620873665C2776694085 @default.
• W2620873665 hasConceptScore W2620873665C2776755627 @default.
• W2620873665 hasConceptScore W2620873665C2777872185 @default.
• W2620873665 hasConceptScore W2620873665C2778119113 @default.
• W2620873665 hasConceptScore W2620873665C2778336483 @default.
• W2620873665 hasConceptScore W2620873665C2778476033 @default.
• W2620873665 hasConceptScore W2620873665C2778559949 @default.
• W2620873665 hasConceptScore W2620873665C2779050716 @default.
• W2620873665 hasConceptScore W2620873665C2779338263 @default.
• W2620873665 hasConceptScore W2620873665C2779429289 @default.
• W2620873665 hasConceptScore W2620873665C2779725641 @default.
• W2620873665 hasConceptScore W2620873665C2780317896 @default.
• W2620873665 hasConceptScore W2620873665C2911091166 @default.
• W2620873665 hasConceptScore W2620873665C71924100 @default.
• W2620873665 hasConceptScore W2620873665C90924648 @default.
• W2620873665 hasIssue "22" @default.
• W2620873665 hasLocation W26208736651 @default.
• W2620873665 hasOpenAccess W2620873665 @default.
• W2620873665 hasPrimaryLocation W26208736651 @default.
• W2620873665 hasRelatedWork W2026642219 @default.
• W2620873665 hasRelatedWork W2121694206 @default.
• W2620873665 hasRelatedWork W2142444726 @default.
• W2620873665 hasRelatedWork W2155499847 @default.
• W2620873665 hasRelatedWork W2183352065 @default.
• W2620873665 hasRelatedWork W2401224456 @default.
• W2620873665 hasRelatedWork W2417263034 @default.
• W2620873665 hasRelatedWork W2620873665 @default.
• W2620873665 hasRelatedWork W4282915667 @default.
• W2620873665 hasRelatedWork W4295128659 @default.
• W2620873665 hasVolume "128" @default.

• next